The many faces of psoriatic arthritis - a challenge to treatment to target?
作者信息
Aletaha Daniel
机构信息
Division of Rheumatology, Medical University of Vienna, Vienna, Austria.
出版信息
Reumatologia. 2016;54(1):1-2. doi: 10.5114/reum.2016.58753. Epub 2016 Mar 23.
Abstract
摘要
相似文献
1
The many faces of psoriatic arthritis - a challenge to treatment to target?
Reumatologia. 2016;54(1):1-2. doi: 10.5114/reum.2016.58753. Epub 2016 Mar 23.
2
Early psoriatic arthritis: facing the challenge.
Br J Nurs. 2013;22(17):1014-20. doi: 10.12968/bjon.2013.22.17.1014.
3
Psoriatic arthritis: a diagnostic challenge?
G Ital Dermatol Venereol. 2010 Jun;145(3):407-14.
4
Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial.
Lancet. 2000 Jul 29;356(9227):385-90. doi: 10.1016/S0140-6736(00)02530-7.
5
Recommendations for the coordinated management of psoriatic arthritis by rheumatologists and dermatologists: a Delphi study.
Actas Dermosifiliogr. 2014 Apr;105(3):216-32. doi: 10.1016/j.adengl.2013.07.003. Epub 2014 Mar 20.
6
[The role of biological agents in the treatment of psoriatic arthritis, literature review].
Orv Hetil. 2006 Oct 15;147(41):1963-70.
7
Association of rheumatoid factor and uric acid with psoriatic arthritis: a review.
Mymensingh Med J. 2014 Jul;23(3):609-13.
8
Plasma YKL-40: a potential biomarker for psoriatic arthritis?
J Eur Acad Dermatol Venereol. 2013 Jul;27(7):815-9. doi: 10.1111/j.1468-3083.2012.04570.x. Epub 2012 May 23.
9
Early biomarkers of joint damage in rheumatoid and psoriatic arthritis.
Arthritis Res Ther. 2015 Jun 1;17(1):141. doi: 10.1186/s13075-015-0652-z.
10
Psoriatic arthritis: a clinical entity distinct from psoriasis?
Rev Bras Reumatol. 2012 Aug;52(4):630-8.
引用本文的文献
1
Higher Incidence Rates of Comorbidities in Patients with Psoriatic Arthritis Compared with the General Population Using U.S. Administrative Claims Data.
J Manag Care Spec Pharm. 2019 Jan;25(1):122-132. doi: 10.18553/jmcp.2018.17421. Epub 2018 Apr 25.
2
Important Treatment Outcomes for Patients with Psoriatic Arthritis: A Multisite Qualitative Study.
Patient. 2017 Aug;10(4):455-462. doi: 10.1007/s40271-017-0221-4.
本文引用的文献
1
Pharmacological treatment of psoriatic arthritis: a systematic literature review for the 2015 update of the EULAR recommendations for the management of psoriatic arthritis.
Ann Rheum Dis. 2016 Mar;75(3):490-8. doi: 10.1136/annrheumdis-2015-208466. Epub 2015 Dec 11.
2
European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update.
Ann Rheum Dis. 2016 Mar;75(3):499-510. doi: 10.1136/annrheumdis-2015-208337. Epub 2015 Dec 7.
3
Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force.
Ann Rheum Dis. 2014 Jan;73(1):6-16. doi: 10.1136/annrheumdis-2013-203419. Epub 2013 Jun 8.
4
Application of the DAREA/DAPSA score for assessment of disease activity in psoriatic arthritis.
Ann Rheum Dis. 2010 Aug;69(8):1441-7. doi: 10.1136/ard.2009.122259. Epub 2010 Jun 4.
5
Epidemiology of psoriatic arthritis in the population of the United States.
J Am Acad Dermatol. 2005 Oct;53(4):573. doi: 10.1016/j.jaad.2005.03.046.
6
Psoriatic arthritis: epidemiology, clinical features, course, and outcome.
Ann Rheum Dis. 2005 Mar;64 Suppl 2(Suppl 2):ii14-7. doi: 10.1136/ard.2004.032482.
7
Interpretation and power of a pooled index.
J Rheumatol. 1993 Mar;20(3):575-8.
Zotero 插件